PET Imaging in Potentially Surgically Resectable Non-small Cell Lung Cancers
The Impact of Positron Emission Tomography (PET) Imaging in Staging Potentially Surgically Resectable Non-small Cell Lung Cancers: A Prospective Multicentre Randomized Clinical Trial
Sponsor: Ontario Clinical Oncology Group (OCOG)
This PHASE3 trial investigates Non-small-cell Lung Carcinoma and is currently completed. Ontario Clinical Oncology Group (OCOG) leads this study, which shows 6 recorded versions since 2004 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Jul 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ontario Clinical Oncology Group (OCOG)
- Ontario Ministry of Health and Long Term Care
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Hamilton, Canada
- • London, Canada
- • Mississauga, Canada
- • Ottawa, Canada
- • Scarborough Village, Canada
- • Toronto, Canada